Amgen, Inc. announced on 4 March that it will pay $1.9bn to acquire Five Prime Therapeutics, Inc. in a deal that someanalysts see as a potential precursor to larger business development by the company. Amgen’s purchase was motivated by the strength of Five Prime’s Phase III-ready, first-in-class FGFR2b-targeting antibody bemarituzumab in the treatment of HER-negative gastric cancer.
The acquisition gives Amgen a much-needed addition to its late-stage research and development pipeline and the company said it sees potential for bemarituzumab to offer growth
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?